Engraftment syndrome: A common cause for rash and fever following autologous hematopoietic stem cell transplantation for multiple sclerosis

Bone Marrow Transplantation

Volumn 29, Issue 1, 2002, Pages 81-85

  Oyama, Y ^a   Cohen, B ^a   Traynor, A ^a   Brush, M ^a   Rodriguez, J ^a   Burt, R K ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Autologous transplantation; Engraftment syndrome; Eosinophilia; Multiple sclerosis; Skin rash

Indexed keywords

AVENOX; AZATHIOPRINE; CARMUSTINE; CIPROFLOXACIN; CLADRIBINE; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; GLATIRAMER; GRANULOCYTE COLONY STIMULATING FACTOR; INTERFERON BETA SERINE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PENTAMIDINE; PIPERACILLIN PLUS TAZOBACTAM; PREDNISONE; VALACICLOVIR;

ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENGRAFTMENT SYNDROME; EOSINOPHILIA; FATIGUE; FEMALE; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LASSITUDE; LEUKAPHERESIS; LUNG DISEASE; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PRURITUS; RASH; SYMPTOMATOLOGY; SYNDROME; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 0036159001     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703324     Document Type: Article

References (36)

1. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial
2. Interferon (beta)-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial
3. Randomised double-blind placebo-controlled study of interferon (beta)-1a in relapsing/remitting multiple sclerosis
4. Placebo-controlled multicentre randomised trial of interferon (beta)-1b in treatment of secondary progressive multiple sclerosis
5. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
6. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial
7. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability
8. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome
9. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomised multicentre study of active disease using MRI and clinical criteria
10. Cause of death in patients attending multiple sclerosis clinics
11. Bone marrow transplantation for multiple sclerosis
12. Viral hyperinfection of the central nervous system and high mortality after hematopoietic stem cell transplantation for treatment of Theiler's murine encephalomyelitis virus-induced demyelinating disease
13. Stem cell transplantation in experimental models of autoimmune disease
14. Acute/relapsing experimental autoimmune encephalomyelitis: Induction of long lasting, antigen-specific tolerance by syngeneic bone marrow transplantation
15. Effect of disease stage on clinical outcome after syngeneic bone marrow transplantation for relapsing experimental autoimmune encephalomyelitis
16. Effective treatment of relapsing experimental autoimmune encephalomyelitis with pseudoautologous bone marrow transplantation
17. Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation
18. Treatment of experimental allergic encephalomyelitis in rats with total body irradiation and syngeneic BMT
19. Treatment of relapsing experimental autoimmune encephalomyelitis in rats with allogeneic bone marrow transplantation from a resistant strain
20. Syngeneic bone marrow transplantation eliminates V beta 8.2 T lymphocytes from the spinal cord of Lewis rats with experimental allergic encephalomyelitis
21. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: First results of a pilot study
22. T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: Report on the first three patients
23. Autologous stem cell transplantation in progressive multiple sclerosis - An interim analysis of efficacy
24. Treatment of severe multiple sclerosis (MS) with high-dose immunosuppressive therapy (HDIT) and autologous stem cell transplantation (SCT)
25. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: Report of toxicity and immunological monitoring
26. Autologous CD34+ selected hematopoietic stem cell transplantation (CD34+/HSCT) for multiple sclerosis: Update of a single center experience in 10 patients
27. Bone marrow transplantation in multiple sclerosis
28. High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis
29. Major morbidity related to hyperthermia in multiple sclerosis
30. Fever and evoked potentials in multiple sclerosis
31. An engraftment syndrome in autologous stem cell transplantation related to mononuclear cell dose
32. Engraftment syndrome after autologous peripheral blood stem cell transplantation with high numbers of peripheral blood stem cells followed by granulocyte colony-stimulating factor administration
33. Autoaggression syndrome resembling acute graft-versus-host disease grade IV after autologous peripheral blood stem cell transplantation for breast cancer
34. Clinical evidence for an engraftment syndrome associated with early and steep neutrophil recovery after autologous blood stem cell transplantation
35. Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantation
36. Engraftment syndrome following hematopoietic stem cell transplantation